Hosted by Drug Discovery World and supported by Bio-Techne, this webinar will explore the advances and challenges taking place within the cell and gene therapy field. You will hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo… Read More
R&D teams don’t need another chatbot. They need a team that can act on their behalf, guided by the scientists who know the science best. The future of R&D removes the toil of day-to-day work and connects the data scattered across your systems and teams. In this webinar, taking place… Read More
R&D teams don’t need another chatbot. They need a team that can act on their behalf, guided by the scientists who know the science best. The future of R&D removes the toil of day-to-day work and connects the data scattered across your systems and teams. In this webinar, taking place… Read More
The pharmacological behaviour of drugs is determined not only by their intrinsic properties but also by the sensitivity of the biological systems in which they are evaluated. Variations in receptor density and signal transduction efficiency can significantly influence observed drug responses, complicating the translation of in vitro findings to in… Read More
This digital summit, hosted by DDW and supported by Sino Biological, explores the advances and challenges taking place within the field of immuno-oncology. Featuring expert presentations and a panel discussion, the summit will explore topics such as how to tackle cancer drug resistance, personalised medicine, cytotoxic therapy in the immunotherapy… Read More
Hosted by Drug Discovery World and supported by Bio-Techne, this webinar will explore the advances and challenges taking place within the cell and gene therapy field. You will hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo… Read More
R&D teams don’t need another chatbot. They need a team that can act on their behalf, guided by the scientists who know the science best. The future of R&D removes the toil of day-to-day work and connects the data scattered across your systems and teams. In this webinar, taking place… Read More
R&D teams don’t need another chatbot. They need a team that can act on their behalf, guided by the scientists who know the science best. The future of R&D removes the toil of day-to-day work and connects the data scattered across your systems and teams. In this webinar, taking place… Read More
The pharmacological behaviour of drugs is determined not only by their intrinsic properties but also by the sensitivity of the biological systems in which they are evaluated. Variations in receptor density and signal transduction efficiency can significantly influence observed drug responses, complicating the translation of in vitro findings to in… Read More
This digital summit, hosted by DDW and supported by Sino Biological, explores the advances and challenges taking place within the field of immuno-oncology. Featuring expert presentations and a panel discussion, the summit will explore topics such as how to tackle cancer drug resistance, personalised medicine, cytotoxic therapy in the immunotherapy… Read More
Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development. You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics… Read More
This webinar, hosted by DDW, explores how deep learning and physics-based methods can be combined to improve antibody affinity maturation and epitope mapping using workflows available in BIOVIA Discovery Studio Simulation on the 3DEXPERIENCE cloud platform. Through case studies involving antibody-antigen and nanobody-receptor complexes, the work demonstrates how virtual mutagenesis,… Read More
As sample numbers increase in early-stage development, purification can quickly become a bottleneck. This webinar, hosted by DDW and supported by Cytiva, explores how automation, parallel chromatography, and smart software features can help scientists increase throughput, reduce hands-on time, and maintain consistent purification performance. Learn how multiple chromatography systems can… Read More
Hosted by Drug Discovery World and supported by BioIVT, this webinar examines the advances, challenges and opportunities that exist in neuroscience drug discovery and development. You will hear from a number of experts who will discuss how both technology and scientific approaches are helping enable the development of new therapies… Read More
In drug discovery, valuable scientific insights are often scattered across spreadsheets, slide decks and email threads. Chemistry teams spend hours preparing for update meetings, chasing CRO progress and digging into the data to find out what has been done before. When hypotheses and learnings only live in slides or individual… Read More
AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at Alithea Genomics,… Read More
Many laboratories have invested in automation, yet workflows often remain fragmented, with disconnected instruments, data, and processes creating inefficiencies and limiting scalability. As scientific workflows grow more complex, automation alone is no longer enough. Leading labs are now embracing orchestration, the coordination of instruments, robotics, software, data, and people across the… Read More
Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More
KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More
Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process. Traditional AVA workflows require numerous parallel and sequential assays, often taking weeks to complete and contributing… Read More
Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programmes on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar on 11… Read More
